D.A. Davidson & CO. Sells 68 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

D.A. Davidson & CO. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 753 shares of the biopharmaceutical company’s stock after selling 68 shares during the period. D.A. Davidson & CO.’s holdings in Regeneron Pharmaceuticals were worth $536,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Truist Financial Corp increased its holdings in Regeneron Pharmaceuticals by 59.8% in the 4th quarter. Truist Financial Corp now owns 59,303 shares of the biopharmaceutical company’s stock worth $42,243,000 after purchasing an additional 22,192 shares in the last quarter. CIBC Asset Management Inc increased its stake in shares of Regeneron Pharmaceuticals by 3.1% in the fourth quarter. CIBC Asset Management Inc now owns 34,386 shares of the biopharmaceutical company’s stock valued at $24,494,000 after buying an additional 1,034 shares during the period. Human Investing LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $61,000. AlphaCentric Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $350,000. Finally, Americana Partners LLC increased its stake in shares of Regeneron Pharmaceuticals by 11.5% in the fourth quarter. Americana Partners LLC now owns 350 shares of the biopharmaceutical company’s stock valued at $249,000 after buying an additional 36 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Sanford C. Bernstein decreased their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Citigroup decreased their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Finally, Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Up 1.4 %

REGN stock opened at $723.47 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock’s 50 day moving average is $698.84 and its 200-day moving average is $875.48. The firm has a market capitalization of $79.09 billion, a PE ratio of 18.90, a P/E/G ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the company earned $11.86 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.